Latest News

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.

As psychedelic medicines near approval, pharmacists will become essential guides in safety and education.

From embedded PrEP care to rapid outbreak response logistics, new models are showing how pharmacists can establish successful public health partnerships to enhance patient access and equity.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.

Compared with late postmenopausal women, menopausal hormone therapy (MHT) may influence certain Alzheimer disease-related biomarkers in early postmenopausal women.

Discover effective solutions for dry eyes, contact lens care, allergy relief, and conjunctivitis treatment in these insightful case studies.

While long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

Increasing vaccine confidence demands that pharmacists move beyond simply sharing facts to utilizing effective communication strategies.

Pharmacists play a vital role in managing respiratory virus season by providing vaccinations, counseling, and recommending effective treatments for patients.

Long-term findings from the REASSURE study confirm Radium-223’s acceptable hematologic safety profile and reinforce the importance of early use alongside bone-protecting agents to minimize fracture risk and optimize outcomes.

Personalized cancer vaccines target tumor heterogeneity, enhancing immune responses and improving treatment outcomes in diverse cancer types.

Experts at ESMO 2025 highlight antibody-drug conjugates in HER2-positive metastatic breast cancer treatment.

Emerging biomarkers and targeted therapies are reshaping the landscape of lung cancer treatment and drug development.

Advances in targeted therapies, combination approaches, and novel treatment strategies are shaping the management of drug-resistant lung cancer.

Insights from ESMO 2025 highlight advancements in non-small cell lung cancer treatment, focusing on novel therapies and molecular diagnostics.

New data from the NATALEE trial reveals ribociclib significantly improves invasive disease-free survival in HR+/HER2– early breast cancer.

Adjuvant abemaciclib plus endocrine therapy significantly enhances overall survival in high-risk HR-positive HER2-negative breast cancer.

Durvalumab combined with FLOT shows significant survival benefits for patients with resectable gastroesophageal junction cancer, regardless of PD-L1 status.

Students can better balance parenthood, academics, and self-care with planning, resilience, and strong support systems.

Novel mechanism offers hope for improved tolerability and efficacy in patients facing resistance or long-term toxicity with existing TKIs.